Oncolytics Biotech Reports Promising Pelareorep Data in Cancer Treatment

Oncolytics Biotech has announced promising clinical data for pelareorep, demonstrating strong survival benefits in metastatic pancreatic ductal adenocarcinoma and HR+/HER2- metastatic breast cancer. The data shows a two-year survival rate of 21.9% in pancreatic cancer and a median overall survival benefit of over 10 months in breast cancer. The company plans to leverage its fast-track status to expedite regulatory pathways for pelareorep's advancement.

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has announced promising clinical data for its immunotherapy treatment, pelareorep, demonstrating strong survival benefits in metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer patients. The company reported a two-year survival rate of 21.9% in mPDAC patients receiving pelareorep, compared to a 9.2% historical benchmark. Additionally, the company cited a 62% objective response rate when pelareorep was combined with chemotherapy and a checkpoint inhibitor. In HR+/HER2- metastatic breast cancer studies, pelareorep showed median overall survival benefits exceeding 10 months compared to standard chemotherapy treatments. The BRACELET-1 study showed median progression-free survival of 12.1 months for patients receiving pelareorep with paclitaxel versus 6.4 months for those receiving paclitaxel alone [1].

Oncolytics Biotech plans to leverage its fast-track status to expedite regulatory pathways for pelareorep's advancement. The company aims to take pelareorep directly into registration-enabling trials, utilizing its fast-track status to find the most efficient regulatory path forward this summer [1].

The clinical-stage biotechnology company's stock is currently trading near its Fair Value, reflecting market confidence in its clinical developments [2].

References:

[1] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-highlights-transformative-pelareorep-survival-data-in-multiple-tumors-and-commitment-to-registration-enabling-studies/
[2] https://www.investing.com/news/company-news/oncolytics-biotech-reports-improved-survival-rates-in-cancer-studies-93CH-4126610